Evidence map›Paper›PMID 40661530›Full record

ArticlebioRxiv : the preprint server for biology2025

Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia.

Bogdan Popescu, Matthew F Jones, Madison Piao, Elaine Tran, Andrew Koh, Isabelle Lomeli, Cheryl A C Peretz, Natalia Murad, Sydney Abelson, Carolina Morales and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Bogdan PopescuDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-7960-5218
Matthew F JonesDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Madison PiaoDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Elaine TranDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Andrew KohDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Isabelle LomeliDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Cheryl A C PeretzDepartment of Pediatrics, Division of Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-0855-6770
Natalia MuradDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Sydney AbelsonDepartment of Pediatrics, Division of Oncology, University of California San Francisco, San Francisco, CA, USA.
Carolina MoralesDepartment of Pediatrics, Division of Oncology, University of California San Francisco, San Francisco, CA, USA.
Jose M RiveraDepartment of Pediatrics, Division of Oncology, University of California San Francisco, San Francisco, CA, USA.
Yana PikmanDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5336-0216
Michael L ChengDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Aaron C LoganDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1179-5879
Elliot StieglitzDepartment of Pediatrics, Division of Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-7032-4623
Catherine C SmithDepartment of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-0160-7026

Funding

Investigating the mechanism of SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia (AML)R01CA277031 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Catherine Choy Smith · 2023 to 2026
$1.9M
NCI NIH HHS R01 CA277031
6 · The paper itself

Abstract

Aberrant activation of the RAS/MAPK signaling limits the clinical efficacy of several targeted therapies in acute myeloid leukemia (AML). In

Identifiers

PMID40661530
PMCPMC12259086

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.